MSN Generic Entresto Launch In Doubt After US Appeals Court Stops Approval

 
• By Dean Rudge

MSN Laboratories will be unable to move forward with any potential ‘at-risk’ launch for its generic version of Novartis’ Entresto blockbuster in the US for now after the originator won a stay of the firm’s ANDA approval pending appeal from the US Court of Appeals for the District of Columbia Circuit.

Pause
A federal appeals court disagreed with lower court rulings on the Entresto generic. • Source: Shutterstock: studiostoks

More from Generics

More from Biosimilars & Generics